This first session in a two-part EASL DeepDive series on the 2024 EASL-EASD-EASO MASLD Clinical Practice Guidelines will provide a detailed examination of the recommendations concerning diagnosis, non-invasive assessment, and risk stratification, with a view to supporting evidence-based clinical practice.

Learning objectives

• Have a good understanding of the concept/definition of MASLD within the framework of the new SLD nomenclature, including its contribution to disease progression in other diseases
• Get familiar with the role of non-invasive tests for risk stratification in MASLD, their pro- and cons, and how and in whom to use them for screening/case finding
• Get a detailed understanding of HCC risk and risk stratification in MASLD and the surveillance strategies to implement

This programme is part of the EASL Guidelines Implementation Programme on MASLD supported by Boehringer Ingelheim and Novo Nordisk. Boehringer Ingelheim and Novo Nordisk have had no input in the selection and creation of this programme.

This episode addresses key challenges in vascular complications of liver disease, including the management of portal vein thrombosis (PVT) in patients with and without cirrhosis. Experts will explore controversies surrounding long-term anticoagulation therapy and discuss insights from the CIRROXABAN paper. Additionally, the episode will shed light on the management of splanchnic artery aneurysms, offering valuable guidance for clinical practice.

Moderator:  Pierre-Emmanuel Rautou;

Faculty: Sarwa Darwish Murad, Juan-Carlos Garcia-Pagan, Valérie Vilgrain 

Related episodes

• S4E11 – YI Choice: Gene therapy for liver disease — RNA interference and beyond
• S4E6 – Regenerating the liver graft with a machine?
• S3E11 – Regenerative Hepatology: From stem cells to tissue engineering
• S2E9 – YI Choice: Propelling liver cell biology into the third dimension

All EASL Studio Podcasts are available on EASL Campus.

Click here to see all EASL Video Podcasts on Apple Podcasts.

In this new edition of the EASL DeepDive, expert faculty guide participants through a focused and forward-looking discussion on key aspects of advanced MASLD, setting the stage for a deeper understanding of evolving clinical challenges and opportunities.

This EASL DeepDive webinar is supported by Boehringer Ingelheim. Boehringer Ingelheim has had no input into the content of this EASL DeepDive.

Learning objectives

• Understand the Pathophysiology: Describe the key pathophysiological mechanisms of MASLD and its progression to advanced liver disease and portal hypertension.
• Identify Unmet Clinical Needs: Recognise the current gaps in diagnosis, management, and treatment of advanced MASLD, highlighting the challenges of healthcare professionals in clinical practice.
• Evaluate Valuable Endpoints: Discuss the importance of selecting and utilising valuable clinical endpoints in managing MASLD to improve patient outcomes.
• Explore Emerging Therapies: Review the latest therapeutic strategies and potential interventions for advanced MASLD, focusing on how they address the unmet needs in patient care.

All EASL DeepDive are available on EASL Campus.

This EASL Studio episode explores state-of-the-art practices in diagnosing steatotic liver disease and stratifying patients effectively for targeted treatment in 2025. Focusing on integrating cardiometabolic risk profiling and dynamic alcohol consumption assessment, the discussion will discuss contemporary methods, frequency, and practical implementation in clinical settings to enhance precision medicine approaches.

Moderator: Aleksander Krag 

Faculty: Meena Bansal, Mattias Ekstedt, Arun Sanyal 

All EASL Studio Podcasts are available on EASL Campus.

Click here to see all EASL Video Podcasts on Apple Podcasts.

Listen to this EASL Studio episode to explore how artificial intelligence (AI) is transforming healthcare. Discuss its potential to revolutionise medical practice, its limitations, and whether it poses a threat or an opportunity for the future of the medical profession.

Moderator: Ahmed Elsharkawy  

Faculty: Jakob Kather, Sabela Lens, Ashley Spann 

Related episodes:

• EASL Studio at EASL Congress 2024 – Exploring new frontiers: The AI liver taskforce initiative
• S4E5 – AI for dummies
• S2E13 – Digital Pathology

All EASL Studio Podcasts are available on EASL Campus.

Click here to see all EASL Video Podcasts on Apple Podcasts.

With the release of the new HBV guidelines, treatment eligibility broadens. This EASL Studio explores how to communicate these changes, support shared decision-making, ensure adherence, and engage patients in ongoing care and clinical trials.

Moderator: Ahmed Elsharkawy 

Faculty: Markus Cornberg, Sital Shah, Thomas Tu, Su Wang

This EASL Studio is supported by Aligos Therapeutics and Gilead Sciences Europe Ltd . EASL has received no input from Aligos Therapeutics or Gilead Sciences Europe Ltd with regards to the content of this programme.

All EASL Studio Podcasts are available on EASL Campus.

Click here to see all EASL Video Podcasts on Apple Podcasts.

Listen to this EASL Studio episode for insights on the new MASLD guidelines and their practical application. Hear from experts on navigating the nomenclature change, implementing guidelines in clinical workflows, and fostering behavioral change to improve patient outcomes across the care team.

Moderator: Sven Francque 

Faculty: Marta Cervera, Elena George, Shelley Keating

This programme is part of the EASL Guidelines Implementation Programme on MASLD supported by Boehringer Ingelheim and Madrigal Pharmaceuticals. Boehringer Ingelheim or Madrigal Pharmaceuticals have had no input in the selection and creation of this programme.

Related episode

• S5E5 – JHEP Live: The new nomenclature for SLD: A multidisciplinary evaluation and approach

All EASL Studio Podcasts are available on EASL Campus.

Click here to see all EASL Video Podcasts on Apple Podcasts.

Listen to this episode for a curated overview of landmark studies and breakthrough data presented at EASL Congress 2025, with expert insights on their clinical relevance and impact on the future of hepatology.

Moderator: Thomas Berg 

Faculty: Hannes Hagström, Verena Keitel, Raj Mookerjee

All EASL Studio Podcasts are available on EASL Campus.

Click here to see all EASL Video Podcasts on Apple Podcasts.

Most liver diseases are diagnosed when it’s already too late. This episode explores the pros and cons of early screening, the gaps in current strategies, and how projects like LIVERAiM are aiming to change the game.

Moderator: Ahmed Elsharkawy

Faculty: Pere Ginès, Ian Rowe, Maja Thiele

All EASL Studio Podcasts are available on EASL Campus.

Click here to see all EASL Video Podcasts on Apple Podcasts.

This EASL Studio episode cuts through the noise to explore alcohol’s true impact on health and society, spotlighting patient stories, public misconceptions, and bold policy solutions from across Europe.

Moderator: David Barret (Internal Communications and Multimedia Manager, WHO Regional Office for Europe)

Faculty: Carina Ferreira-Borges (Regional Advisor for Alcohol, Illicit drugs and Prison health, WHO Regional Office for Europe), Aleksander Krag (EASL Secretary General), Hazel Martin (BBC Journalist and Liver Patient), Margarida Santos (General Practitioner Portugal), Riina Sikkut (Member of Estonian Parliament, former Minister of Health of Estonia)

All EASL Studio Podcasts are available on EASL Campus.

Click here to see all EASL Video Podcasts on Apple Podcasts.